Potassium Ion

Potassium Ion

SCHEMBL302491

CCC(C(C)=O)C(=O)[O-].[K+]

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA

The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.39
TSHR P16473 2/20 0.39
NFKB1 P19838 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
CA4 P22748 2/20 0.38
CA2 P00918 1/20 0.37
CA1 P00915 4/20 0.35
FFAR3 O14843 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10415391 0.95 CYP3A4 (0.39) CYP3A4TSHRNFKB1NPSR1CA4
SCHEMBL968034 0.95 CYP3A4 (0.39) CYP3A4TSHRNFKB1NPSR1CA4
SCHEMBL21219167 0.95 CYP3A4 (0.39) CYP3A4TSHRNFKB1NPSR1CA4
SCHEMBL21219181 0.95 CYP3A4 (0.39) CYP3A4TSHRNFKB1NPSR1CA4
SCHEMBL21219179 0.95 CYP3A4 (0.39) CYP3A4TSHRNFKB1NPSR1CA4
SCHEMBL21219171 0.95 CYP3A4 (0.39) CYP3A4TSHRNFKB1NPSR1CA4
SCHEMBL21519878 0.95 CYP3A4 (0.39) CYP3A4TSHRNFKB1NPSR1CA4
SCHEMBL21219173 0.95 CYP3A4 (0.39) CYP3A4TSHRNFKB1NPSR1CA4
SCHEMBL21219169 0.95 CYP3A4 (0.39) CYP3A4TSHRNFKB1NPSR1CA4
SCHEMBL9577856 0.95 CYP3A4 (0.39) CYP3A4TSHRNFKB1NPSR1CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2012500848-A 2012-01-12 JP claimed
US-8044214-B2 Process for preparing isoxazole compounds ANGUS CHEMICAL COMPANY (US) 2011-10-25 US claimed
EP-2318381-A1 PROCESS FOR PREPARING ISOXAZOLE COMPOUNDS Dow Global Technologies LLC (US) 2011-05-11 EP claimed
WO-2010025035-A1 PROCESS FOR PREPARING ISOXAZOLE COMPOUNDS DOW GLOBAL TECHNOLOGIES INC. (US) 2010-03-04 WO claimed
US-20100048910-A1 PROCESS FOR PREPARING ISOXAZOLE COMPOUNDS ANGUS CHEMICAL COMPANY 2010-02-25 US claimed
EP-2599840-B1 SILVER INK COMPOSITION AND BASE MATERIAL TOPPAN FORMS CO LTD (JP) 2018-07-25 EP disclosed
US-9328254-B2 Silver ink composition and substrate TOPPAN FORMS CO., LTD. (JP) 2016-05-03 US disclosed
EP-2599840-A1 SILVER INK COMPOSITION AND BASE MATERIAL Toppan Forms Co., Ltd. (JP) 2013-06-05 EP disclosed
US-20130121872-A1 Silver Ink Composition and Substrate TOPPAN FORMS CO., LTD. (JP) 2013-05-16 US disclosed
US-8044214-B2 Process for preparing isoxazole compounds ANGUS CHEMICAL COMPANY (US) 2011-10-25 US disclosed
EP-2318381-A1 PROCESS FOR PREPARING ISOXAZOLE COMPOUNDS Dow Global Technologies LLC (US) 2011-05-11 EP disclosed
WO-2010025035-A1 PROCESS FOR PREPARING ISOXAZOLE COMPOUNDS DOW GLOBAL TECHNOLOGIES INC. (US) 2010-03-04 WO disclosed
US-20100048910-A1 PROCESS FOR PREPARING ISOXAZOLE COMPOUNDS ANGUS CHEMICAL COMPANY 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048910-A1 PROCESS FOR PREPARING ISOXAZOLE COMPOUNDS CYP11B2, CYP11B1, CYP3A7 CYP3A4 12/4885TSHR 3112/4885NFKB1 851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.